Nivolumab extends survival for NSCLC

Bookmark and Share
Published: 29 May 2015
Views: 2336
Rating:
Save
Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares presents at ASCO 2015 data from a randomised phase III study that indicate PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).

Read the news article and watch the interview.